By Mo Krochmal
Can Roche convince the US Food and Drug Administration that its micro-arrays should be approved as analyte-specific reagents? That remains to be seen, but microarray producers with hopes for penetrating the lucrative in vitro diagnostic and clinical marketplaces have been watching closely since FDA sent Roche a letter in July questioning its claim that the AmpliChip CYP450 microarray qualifies as an analyte-specific reagent.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
